The Supposition of the Mechanism of SSRI to the glossodynia as Non-Organic-Pain in the Mouth and Face Area by OHKUBO Tsunemasa et al.
11高山赤十字病院紀要　第41号：p11－13（2017）
The Supposition of the Mechanism of SSRI to the glossodynia 
as Non-Organic-Pain in the Mouth and Face Area
Tsunemasa OHKUBO１）,  Toshihiro ANDO２）　and Hideaki KATO３）　
１）Japanese Red Cross Takayama Hospital, Department of Dentistry and Oral Surgery, Takayama Japan
２）Japanese Red Cross Takayama Hospital, Department of Psyhological medicine, Takayama Japan
３）Suda mental hospital, Takayama Japan
　These contents obtain the approval of Japanese Red Cross Takayama Hospital Ethics Committee 
and it is considering sufficiently about the ethical models such as the protection of the privacy.
There is not a state of the conflict of interests (COI).
【 Key Words 】Glossodynia, SSRI, Escitalopram, 5-HT, Phasic dopamine, β-endorphin
Ⅰ　Introduction
　At the life-support of the animal which 
contains a human being, it is important as for the 
feeling of pain, the pressure of the postoperative 
pain, neuropathic pain or pschosocial background 
in addition to the inflammation are merely 
influenced by more than one piece of cause. 
　The glossodynia is not a little non-organic-
pain in the clinical condition which is near 
the hypochondriasis (it is the C article of the 
physical symptoms disorder in DSM-5). 　　　　
　On the other hand, the  remission　or 
disappearance of the  chronic pain by tricyclic 
antidepressants ( TCA ) have been always 
accepted in the clinical scene. In recent years, 
new anti-depressants of SNRI or SSRI and so on 
became clinical and available in Japan and the 
width of the choice spread. However, there is 
little effective report to the chronic pain in Japan 
to SSRI that an adaptation disease does not have 
an effect. 
　We report because it verified the effectivity 
of Escitalopram of SSRI for the glossodynia 
which is accompanied by an anxiety disorder or 
depressive state.  Moreover, the production of 
effect is added considering about the permitted 
action mechanism from the early stage.
Ⅱ　Methods
　From 2013 in 3 years and half-year of the 
pasts, we treated with Escitalopram of SSRI 
for 45 female and 5 male of the glossodynia 
which complained of the non-organic-pain.  The 
evaluation used Visual Analogue Scale (VAS). 
　It evaluated the effectivity of Escitalopram on 
retrospective study.
　It used corresponding t - test ( improvement 
rate ) and  χ2 - test ( the comparison among the 
groups ) which is compatible with the significant 
test for it and it judged that there was a 
significant difference about p<0.05.
Ⅲ　Results
　The patients who could not continue a 
treatment until 2 week after was 10 examples 
on not coming to hospital: 5 cases, nausea 3 and 
vertigo 2 cases.
　Patient characteristics: About 90 percent of 
women, it is 30 % of depressed states, 65 % of 
anxiety disorder. There were many 70 percent 
and old patients in above the sixty something 
within an average of 65.7 years old.
　VAS score  was improved  from the early 
stage; start of therapy 6.45±1.97, after 1 
week administration of Escitalopram 5.6±
2.32 (p=0.008)、 after 2 week administration of 
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Escitalopram 2.65±2.(57 (p=2.1×10-12)
　Remission rate (VAS=0) of the glossodynia 
was increased from the early stage on 1W: 5%, 
2W: 42.5%, 4W: 75%.
Ⅳ　Discussion
　Escitalopram (5 to 20 mg activity) of SSRI 
had an effect on the patients of glossodynia with 
anxiety disorder or depressive state.  About 
half patients were disappeared from glossodynia 
within 2 weeks early and 75% of patients were 
disappeared from glossodynia within 4 weeks1). 
Escitalopram of SSRI may be useful for chronic 
pain of the head and neck area such as the 
glossodinia symptom and the atypical-facial-
pain. It was effective for the cases that SNRI 
was ineffective2). It is said that there is a pain 
reduction which is equal to duloxetine 60 mg 
in escitalopram 20 mg to the chronic lumbago3). 
Otto and others4) are reporting that the pain 
reduces by the double-blind which prescribed 
escitalopram 20 mg a day for the cases of the 
painful neuropathy.
　The chronic pain disappearance operation 
by antidepressant (escitalopram) which was 
reported in this time seems to be earlier than 
the manifestation of the antidepressant effect 
which is said to be equal to or more than 2 ～ 4 
weeks generally.
　Therefore, We added considering below 
about the possibility of the mechanism that 
Esc i ta lopram of  SSRI shows immediate 
effectivity in the glossodynia that is a non-
organic chronic pain.
Fig　1: The figure of left end is health status, the figure of center is chronic pain condition and the figure of 
right end is the mechanism of the chronic pain restraint behind the escitalopram of SSRI internal use.
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Ⅴ　 Conclusions
　Escitaloplam which is SSRI was prescribed 
to 40 patients of the glossodynia. The pain 
disappearance from the early stage seemed to be 
earlier than the operation manifestation time of 
antidepressant which is explained in the 5-HT1A 
receptor down regulation. Therefore, it logically 
estimated the different chronic pain restraint 
mechanism which acts only in 5-HT. It pointed 
out the possibility that the phasic dopamine 
increase by 5-HT system antidepressant from 
the ventral tegmental area and the β-endorphin 
increase from the corpus striatum and the 
globus pallidus which is caused by this anticipate 
in the manifestation of the very early chronic 
pain improvement effect of escitalopram which 
is seen by the chronic  pain patients5)(Fig 1).
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